Key result
Elevated AIP linked to ~161% greater odds of subclinical systolic dysfunction in obese patients.
Why the study?
Obesity is an independent risk factor for subclinical cardiac systolic dysfunction, but the potential association between atherogenic index of plasma and early cardiac systolic impairment in obese populations remains unclear.
Is the atherogenic index of plasma associated with subclinical cardiac systolic dysfunction in obese patients?
Cross-Sectional (n=615)
No
Is the atherogenic index of plasma associated with subclinical cardiac systolic dysfunction in obese patients?
Odds Ratio: 2.612 (95% CI 1.007–6.778)
Absolute Event Rate: 65.36% vs 44.44%
p-value: p=0.048
Elevated atherogenic index of plasma is independently associated with subclinical cardiac systolic dysfunction in obese individuals, suggesting its potential as a biomarker for early screening.
May support AIP for subclinical dysfunction screening in obese patients; hypothesis-generating and requires prospective validation.
Background Atherogenic index of plasma (AIP) is a novel and sensitive lipid-related biomarker closely associated with metabolic disorders and cardiovascular risk. Obesity is an independent risk factor for subclinical cardiac systolic dysfunction (SD), while the potential association between AIP and early cardiac systolic impairment in obese populations remains unclear. This study aimed to investigate the relationship between AIP and subclinical cardiac SD in obese adults. Methods A cross-sectional study was conducted among 1,070 obese patients between 2019 and 2024. Clinical and biochemical parameters of obese patients were collected on the same day as echocardiographic image acquisition. Subclinical cardiac SD was defined via left ventricular (LV) global longitudinal strain (GLS) from speckle-tracking echocardiography. The logarithm of triglycerides/high-density lipoprotein cholesterol ratio is AIP. Patients were stratified by AIP levels, and regression models were constructed to explore the association between the AIP and subclinical cardiac SD in obese patients. Results After patients were stratified by AIP levels AIP quartiles, the LV GLS absolute value in obese individuals with high AIP levels was significantly reduced compared to obese individuals with low AIP levels ( p < 0.001). After the adjustment for the effects of body mass index, heart rate, sex, LV hypertrophy, LV ejection fraction, age, presence of hypertension, presence of diabetes, blood urea nitrogen and serum creatinine level in the multivariate regression model, AIP > 0.3661 was an independent influencing factor for absolute LV GLS < 20%. Conclusion Elevated AIP is independently associated with subclinical cardiac SD among obese individuals. AIP may serve as a convenient and trustworthy biomarker for early screening of subclinical cardiac SD among obese individuals, which contributes to the early identification and prevention of obesity-related cardiac impairment.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) conducted a cross-sectional in Obesity (n=615). Atherogenic index of plasma (AIP) vs. Low AIP (AIP ≤ 0.0081) was evaluated on Subclinical cardiac systolic dysfunction (absolute LV GLS < 20%) (OR 2.612, 95% CI 1.007-6.778, p=0.048). Elevated atherogenic index of plasma (AIP > 0.3661) was independently associated with subclinical cardiac systolic dysfunction in obese patients compared to those with low AIP (OR 2.612).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: